Trial Profile
A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Allo 715 (Primary) ; ALLO 647; Cyclophosphamide; Fludarabine; Nirogacestat
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Proof of concept; Registrational
- Acronyms UNIVERSAL
- Sponsors Allogene Therapeutics
- 09 Aug 2023 Planned End Date changed from 1 Dec 2027 to 1 Sep 2027.
- 09 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Sep 2027.
- 09 Aug 2023 Status changed from recruiting to active, no longer recruiting.